Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 3;8(3):e41.
doi: 10.1002/hem3.41. eCollection 2024 Mar.

Luspatercept: A peaceful revolution in the standard of care for myelodysplastic neoplasms

Francesca Vinchi  1   2 , Uwe Platzbecker  3
Affiliations

Luspatercept: A peaceful revolution in the standard of care for myelodysplastic neoplasms

Francesca Vinchi et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Francesca Vinchi: Silence Therapeutics: Research Funding; CSL Vifor: Research Funding; PharmaNutra: Research Funding; RallyBio: Consultancy. Uwe Platzbecker: Janssen: Honoraria; Jazz: Honoraria; Silence Therapeutics: Honoraria; Takeda: Honoraria; Novartis: Honoraria; Abbvie: Honoraria; BMS/Celgene: Honoraria; Geron: Honoraria.

Figures

Figure 1
Figure 1
Structure and mechanism of action of luspatercept. Luspatercept is a recombinant fusion protein consisting of a modified extracellular domain of the activin receptor type IIB (ActRIIB) fused with the Fc domain of immunoglobulin G1 (IgG1). Luspatercept binds transforming growth factor‐β (TGF‐β) superfamily ligands to block their inhibitory effect on erythroid maturation in late‐stage erythroid precursors.
See this image and copyright information in PMC

References

    1. Vinchi F, Hell S, Platzbecker U. Controversies on the consequences of iron overload and chelation in MDS. HemaSphere. 2020;4(3):e357. - PMC - PubMed
    1. Iancu‐Rubin C, Mosoyan G, Wang J, Kraus T, Sung V, Hoffman R. Stromal cell‐mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE‐011), an activin receptor type II ligand trap. Exp Hematol. 2013;41(2):155‐166. - PubMed
    1. Wobus M, Mies A, Asokan N, et al. Luspatercept restores SDF‐1‐mediated hematopoietic support by MDS‐derived mesenchymal stromal cells. Leukemia. 2021;35(10):2936‐2947. - PMC - PubMed
    1. Weidner H, Wobus M, Hofbauer LC, Rauner M, Platzbecker U. Luspatercept mitigates bone loss driven by myelodysplastic neoplasms and estrogen‐deficiency in mice. Leukemia. 2022;36(11):2715‐2718. - PMC - PubMed
    1. Cappellini MD, Marcon A, Fattizzo B, Motta I. Innovative treatments for rare anemias. HemaSphere. 2021;5(6):e576. - PMC - PubMed